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The immunogenicity and e~'cacy of an inactivated whole SIVmac (32H) preparation 
adjuvanted with muramyl dipeptide (SIV-MDP) and a gpl20-enriched SIVmac (32H) 
ISCOM preparation ( SIV- ISCOM), were compared by immunizing four rhesus macaques 
(Macaca mulatta). /bur times with SIV-MDP and four others in the same way with 
SIV-ISCOM. Two monkeys immunized with whole inactivated measles virus (MV) 
adjuvanted with MDP ( M V-MDP) and two monkeys immunized with M V-ISCOM served 
as controls. In the SIV-ISCOM.immunized monkeys higher SIV-specific serum antibody 
titres were ./ound than in the SIV-MDP-immunized monkeys. In contrast to the 
MV-immunized monkeys all SIV-MDP- and SIV-ISCOM-immunized monkeys were 
protected against intravenous challenge 2 weeks q[ier the last immunization with 10 median 
monkey il~fectious doses (MIDso) of  a cell-free SIVmac (32H) challenge stock propagated 
in the human T-cell line C8166. After 43 weeks the protected monkeys were reboosted 
and 2 weeks later rechallenged with 10 MIDso o[ the same virus produced in peripheral 
blood mononuclear cells ( PBMC) from a rhesus macaque, None of these animals proved 
to be protected against his challenge. In a parallel experiment in which the same numbers 
~?f monkeys were immunized in the same way, the animals were challenged intravenously 
with 10 MID~ o of PBMCfrom an SIVmac (32H)-infected rhesus macaque. Two out of  
./our SIV-MDP- and two out of  four SIV-ISCOM-immunized monkeys proved to be 
protected Ji'om S lY  infection. 
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The SlY and HIV-2 macaque models have been used 
extensively for the evaluation of strategies for the 
development ofcandidate vaccines against HIV infection 
in humans 1"2. Although protective immunity to SIV and 
HIV-2 infection has been induced by several experimental 
immunization strategies, including live attenuated and 
inactivated virus preparations 3 ~5, in only a few cases 
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was it possible to show that the protection induced was 
the result of SIV-specific immunity. It has been shown 
recently that live attenuated SIV with a deletion in the 
nefgene induced protection against a high dose of SIV 3. 
The only other successful immunization strategy was 
based on a combined approach of infection with 
recombinant vaccinia virus expressing the SIVmac env 
protein and a subsequent boost with purified recombinant 
env protein ~. In all other experiments the protection 
induced with inactivated whole or subunit SIV 
preparations could be attributed to immunity directed 
to cellular proteins present in the vaccine preparations 
usedt6 ~9. 
It may be speculated that for the induction of protective 
immunity to lentivirus infections, both humoral and 
cell-mediated immune responses play a crucial role. In 
our attempts to develop candidate subunit vaccines 
against viruses, we have explored the potential of the 
ISCOM for antigen presentation. This mode of 
presentation has proven to be highly effective in inducing 
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both biologically active antibodies, CD4+ and CD8 + 
T-cell responses and protection from many viruses 
including retroviruses 2°. It has been shown that ISCOMs 
containing HIV-I gpl60 were efficient in inducing 
cross-reactive virus neutralizing (VN) antibodies 21and 
MHC class I-restricted CD8 + T-cell responses 22, both 
of which are considered important in the induction 
of HIV-l-specific protective immunity. In a recent 
experiment, HIV-2 ISCOMs, virtually devoid of viral 
glycoprotein, failed to induce protection to HIV-2 
infection in monkeys ~. In the present study we have 
made a SIVmac (32H) ISCOM preparation enriched for 
gpl20 (SIV-ISCOM), and have compared its immuno- 
genicity in rhesus macaques with an inactivated whole 
SIVmac (32H) preparation adjuvanted with muramyl 
dipeptide (SIV-MDP). Immunized monkeys were 
challenged with either cell-free or cell-associated 
homologous SIV preparations to assess the potential of 
both approaches for the development of candidate 
vaccines against lentivirus infections. 
MATERIALS AND METHODS 
Viruses 
SIV for vaccine production. The 32H isolate of 
SIVmac strain 251 (pool 11/88) was propagated in the 
human T-cell line C8166. Virus was purified from culture 
supernatant by ultracentrifugation a d gel-exclusion 
chromatography as previously described and provided 
for this vaccine trial by programme EVA ~4'~v. For the 
preparation of gpl20-enriched ISCOMs, SIVmac (32H) 
was propagated in C8166 cells (both obtained from M RC 
(ADP 151 and ADP 013 respectively)). SIV-infected cells 
were mixed with three times the number of uninfected 
C8166 cells every 3 4 days, and cultured in 2% fetal calf 
serum (FCS) in RPMI-GPSM for the production of 
cell-flee virus and SIV-infected cells. Cell-flee virus was 
concentrated from clarified culture supernatant of 
SIV-infected C8166 cells by a two-phase extraction 
system as previously described for HIV-123. Briefly, 
clarified culture supernatant was mixed wih 0.3% (w/v) 
Dextran T500 (Pharmacia LKB, Uppsala, Sweden) and 
8% (w/v) polyethlyene glycol 6000 (Merck, Darmstadt, 
Germany). After 3 h incubation at room temperature 
(RT), the mixture was centrifuged for 10min at 
1200revmin ~ The interphase and bottom phase 
containing 40- to 50-fold concentrated virus were 
collected and subsequently reated with 2 % Triton X-100; 
the lysate was clarified by centrifugation (t5 rain at 
2000 rev min- 1). 
SIV challenge stocks. The titrated homologous 
cell-free challenge virus (SIVmac (32H) pool 11/88) 
propagated by short-term culture in C8166 cells was 
kindly provided by Dr M.P. Cranage and has been 
described previously 24'25. An in vitro derived cell- 
associated challenge stock was obtained from an infected 
rhesus macaque (IXC), injected intravenously with 50 
MIDso of the SIVmac (32H) stock 11 months 
postinfection. When the animal showed early-stage 
symptoms of terminal disease, a l rge stock of uncultured 
peripheral blood mononuclear cells (PBMC) was 
prepared and frozen in aliquots 26. A dose of 20000 
PBMC was found to be equivalent o 1 MIDso 
(H. Niphuis, personal communication). Cell-free rhesus 
PBMC-grown SIV challenge stock 5 was produced by 
propagating the SIVmac (32H) pool 11/88 stock in rhesus 
PBMC in vitro and has a titre of 5000 MIDso ml i in 
vivo (S. Norley, personal communication). 
SIV-ISCOM preparations 
Whole SIV ISCOM. Whole SIV ISCOMs were 
prepared from 20mg viable, purified SIVmac (32H), 
provided by EVA, according to standard procedures 
previously described for HIV-1 and HIV-21~'27'28. 
Briefly, the proteins were solubilized with 4% /~- 
octylglucoside (Sigma, St Louis, MO, USA) and mixed 
with 0.1% (w/v) Quil A (Iscotec AB, Lule~t, Sweden) and 
subsequently dialysed. ISCOMs were pelleted through a
10% sucrose cushion and resuspended in phosphate- 
buffered saline (PBS) at a final concentration of 400 #g 
protein ml- 1. 
Gpl20-enriched 1SCOMs. Gpl20 was purified from 
the lysate of the concentrated SIVmac (32H) preparation 
by lentil-lectin affinity chromatography according to 
procedures recommended by the manufacturer (Pharma- 
cia LKB, Uppsala, Sweden). Gp120 was also purified by 
lentil-lectin affinity chromatography from the solubilized 
SIV proteins that were not incorporated into the whole 
SIV ISCOM preparation. The unbound proteins of this 
protein preparation, a p27-enriched preparation, were 
stored for the final SIV-ISCOM vaccine formulation. 
Two methods were used to prepare gpl20-enriched 
ISCOMs. The acidic method has previously been 
described for gpl20 of HIV-127. Briefly, the enriched 
gpl20 preparation (150 pg protein ml l) in 3% fl-octyl- 
glucoside was mixed with purified lipids, brought to 
pH 2.5 with 1 M glycine and thereafter mixed with 0.1% 
Quil A. After sonication and dialysis ISCOMs were 
pelleted through a20% sucrose cushion on a 60% sucrose 
cushion. Gpl20-enriched ISCOMs were also prepared 
by covalent coupling of the protein to a preformed 
ISCOM matrix, which was prepared with lipids 
(phosphatidlyethanolamine and cholesterol) and Quil A 
by dialysis as described previously zg. The ISCOM 
matrix was activated by adding N-succinimidyl 3-(2- 
pyridyldithio)propionate (SPDP; Pierce, Rockford, USA) 
and after 30 rain of incubation at RT, a reduction step 
with dithiothreitol (DTT; Sigma). Activated ISCOM 
matrix was further purified from free SPDP and DTT 
molecules by gel-filtration chromatography over a 
PD-10 column (Sephadex G25, Pharmacia LKB). The 
gpl20-enriched protein preparation (1 mgml ~) was 
activated by adding SPDP in a molar ratio of 1:25. After 
incubation for 30 rain at RT, free SPDP molecules were 
removed by gel-exclusion chromatography over a PD-10 
column. Activated matrix and gpl20 proteins were mixed 
and stirred for 18h at RT. This preparation was 
subsequently ayered over a linear (10--50%) sucrose 
gradient and centrifuged (18h at 41000revmin -~
Beckmann SW41). The gradient was fractionated and 
fractions containing typical ISCOM structures as judged 
by electron microscopy were pooled 3°. 
Formulation and analysis of vaccine preparations 
The inactivated whole SIV vaccine was prepared by 
0.8% formaldehyde treatment of purified SIVmac (32H) 
in 250 #g aliquots by programme EVA 14. Before use this 
preparation was mixed with an equal amount (w/w) of 
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muramyl dipeptide (MDP; Sigma) and diluted to 250/~g 
protein ml-1 in PBS. For consistency between different 
experiments carried out in the framework of the 
EC-concerted action, this formulation was chosen instead 
of the more frequently used MDP oil-and-water 
emulsion. 
The SIV-ISCOM vaccine preparation consisted of a 
mixture of whole SIV ISCOMs, gpl20-enriched ISCOMs 
and a p27-enriched protein preparation. Standardization 
of both SIV vaccine preparations was achieved by 
incorporating approximately th  same amounts of gp 120 
and p27. The amount of p27 present in each ISCOM 
preparation was quantified by the Coulter SIV p27 
antigen detection kit according to procedures recom- 
mended by the manufacturer (Coulter Corp., Hialeah, 
FL, USA). Quantification of gpl20 was carried out by 
ELISA according to a procedure recommended by Dr 
B. McBride (PHLS-CAMR, personal communication). 
Briefly, wells coated with concanavalin A (Con A; 
Pharmacia LKB) were incubated with twofold dilutions 
of the vaccine preparations in 1% Triton X-100 in PBS 
for 2 h at RT. Wells were washed, blocked with 10% FCS 
and 1% BSA in PBS-Tween and subsequently incubated 
with a fixed amount of monoclonal ntibody KK8 (kindly 
provided by K. Kent through MRC) 31. Incubations with 
conjugates and substrate reaction were carried out as 
described for the inhibition ELISA. Recombinant gpl40 
(Repligen Corp., Cambridge, MA, USA) was used as the 
standard protein for the quantification of gpl20. 
Quantitative analysis of the two S1V vaccine preparations 
showed that each dose of 250/~g SIV-MDP contained 
2/~g gpl20 and 10/~g p27, and each dose of SIV-ISCOM 
(120/tg of protein) contained 6-9/~g gpl20, of which 
90-95% was incorporated by the acidic method and 
2-6% by the conjugation method, and 3 #g p27, of which 
96% was derived from the p27-enriched protein 
preparation. 
The SIV vaccine preparations were analysed by SDS- 
polyacrylamide g l electrophoresis (SDS PAGE) on a 
8-25% gradient gel and subsequently Western blot (WB) 
analysis using PhastSystem TM (Pharmacia LKB) according 
to procedures recommended by the manufacturer 
(Application files). For staining of p27, gp32 and gpl20 
proteins monoclonal ntibodies KK33, KK20 and KK8 
were used, respectively (Figure 1) 31. It was shown that all 
these proteins were present in both the SIV-MDP and 
the SIV-ISCOM preparations. Although all virus 
preparations were extensively treated with detergent 
during ISCOM formation, the final SIV-ISCOM 
preparation was further treated with 1:4000 fl- 
propiolactone (Aldrich, Bornem, Belgium) as described 
for inactivated rabies virus vaccine 32. 
Two measles virus (MV) vaccine preparations served 
as controls: purified, fi-propiolactone-inactivated whole 
MV (125/~g/dose) mixed with twice this amount (w/w) 
of MDP and diluted to 1 ml/dose, and a MV-ISCOM 
preparation (10/~g protein per dose). MV, used for the 
preparation of these vaccines, was cultured on Vero 
cells 3°.33. 
Immunization and challenge of rhesus monkeys 
(Macaca mulatta) 
Twenty-four adult, outbred rhesus monkeys, bred in 
captivity at the TNO primate facility, were all shown 
to be free from SIV-specific antibodies, as shown in 
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Figure 1 Characterization of the SIV-MDP (lane 1) and the SIV-ISGOM 
(lane 2) vaccine preparations by WB for the presence of p27, gp120 and 
gp32. Mr markers are indicated 
inhibition ELISAs and WB assay. The monkeys were 
housed under strict isolation conditions at TNO during 
the immunization challenge experiment. All immuniz- 
ations and bleedings were carried out under anaesthesia. 
At 0, 4 and 10 weeks eight monkeys were immunized 
intramuscularly with the SIV-MDP preparation, eight 
monkeys with the SIV-ISCOM preparation, four 
monkeys with MV-MDP and four monkeys with 
MV-ISCOM. At 16 weeks half the monkeys in each group 
were immunized again (group A monkeys) and at 22 
weeks the other 12 monkeys were immunized (group B 
monkeys). Two weeks after the fourth immunization, 12 
monkeys (group A 1) were challenged intravenously with 
10 MIDso homologous cell-free SIVmac (32H) challenge 
virus (2ml of l0 -4 dilution in 10% FCS in PBS). The 
other 12 monkeys (group B) were challenged intravenously 
with l0 MIDs0 SIV-infected PBMC (200000 PBMC per 
2 ml 10% FCS in RPMI). SIV-immunized monkeys of 
group A1, which remained SIV-negative for 43 weeks 
after their first challenge, were boosted with their 
respective SIV preparations and 2 weeks later re- 
challenged with cell-free SIV propagated in rhesus PBMC 
(group A2). Heparinized blood samples were collected at
2-, 3- or 4-weekly intervals during the course of the 
experiments. Clinical symptoms were recorded and 
bodyweights and body temperatures determined. 
Heparinized blood samples were used for haematology, 
serology and virus detection. PBMC were isolated by 
Ficoll gradient centrifugation a d were used for detection 
of viraemia. 
Serology 
WB analysis. SIV antigen was prepared by incubation 
of 1.7 x 107 SIV-infected C8166 cells ml-1 in 0.14 M NaC1, 
10mM Tris-HC1, 2mM MgC12, l mM DTT, 2ram 
phenylmethylsulfonylfluoride an  0.5% Nonidet P-40, for 
60 rain at 0°C. WB strips were prepared by separation of 
clarified cell lysate by 12% SDS PAGE and subsequent 
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transfer to nitrocellulose filters. Strips were blocked for 
l h at RT with 0.1% Tween-80 in PBS (PBS-T) and 
thereafter incubated with 1:50 dilution of monkey plasma 
or 1:500 dilution of monoclonal antibody in PBS-T with 
0.1% BSA, 0.5% non-fat dry milk and 0.001% NaN 3 
overnight at 4°C. After washing in PBS-T, strips were 
subsequently incubated with biotin-conjugated goat-anti- 
human immunoglobulin or goat-anti-murine immuno- 
globulin (Gibco-BRL, Gaithersburg, USA) for 1.5 h and 
alkaline phosphatase-conjugated extravidin (Sigma) for 
1 h. After washing, staining was performed by addition 
of p-nitrotetrazolium blue and 5-bromo-4-chloro-3- 
inodolyl phosphate (BioRad, Richmond, USA). 
Inhibition ELISA. Ninety-six-well high-binding micro- 
ELISA plates (Costar, Cambridge, USA) were coated 
with 100/zg ml 1 Con A and then incubated with 100 pl 
of 1:100 dilution of SIV-infected C8166 cell lysate, as 
described for SIV-WB. Wells were blocked with dilution 
buffer (10% FCS in PBS) and subsequently incubated 
for 1.5 h at 3TC with 50/~1 of fourfold dilutions of 
monkey plasma in dilution buffer. Thereafter, 50/A of 
gpl20-specific or gp32-specific monoclonal antibodies 
(KK56, KK7 respectively) in the appropriate dilution was 
added to the 50/~1 of monkey plasma dilution and 
subsequently incubated for 1 h at 37~'C. The appropriate 
dilution of the monoclonal antibodies was calibrated in 
an indirect SIV-ELISA to give an absorbance at 450 nm 
of 30 50% of the maximum absorbance. Plates 
were incubated with biotin-conjugated goat-anti-murine 
immunoglobulin and horseradish peroxidase (HRPO)- 
conjugated streptavidin (Gibco-BRL) subsequently. The 
biotin anti-murine immunoglobulin conjugate did not 
crossreact with monkey immunoglobulin i  this assay. 
The substrate reaction was carried out with 3,Y,5,5'- 
tetramethylbenzidine as previously described 3°. Inhibition 
titres were defined as the dilution of monkey serum that 
inhibited 50% of the absorbance measured without 
inhibition. Antibodies with specificity for the cellular 
components present in the vaccine preparations, did not 
interfere with the binding of the monoclonal antibodies 
to gpl20 or gp32 (data not shown). 
SIV-neutralization assay. Ten/A of plasma dilutions 
were mixed in U-well microtitre plates (in quadruplicate) 
with 10 l~l of a virus suspension containing 40 infectious 
SIVmac (32H) particles. The plates were briefly shaken 
and incubated for 30min at 37°C in a humidified 
incubator. Next, 200/A of a C8166 suspension (2000 cells) 
were added to each well. After 7 days incubation (37°C, 
4% CO 2, 95% humidity) the individual wells were 
examined microscopically for the presence or absence of 
infected cells, the contents of each well were then 
transferred to poly-L-lysine-coated flat-bottomed micro- 
titre plates and fixed in methanol. The cells were then 
immunochemically stained for the presence of SIV 
antigen using IgG from an infected rhesus monkey 
directly coupled to peroxidase. Wells were again 
examined and only wells with no stained cells were scored 
as negative. The number of negative wells was then used 
to calculate the 'neutralization dose 50 per cent endpoint' 
(NDso) for each sample by the method of Spearmann- 
Karber. 
Cell-ELISA. Cell lysates of uninfected C8166 cells 
and of a pool of rhesus monkey PBMC, derived from 
four SIV-free animals, were prepared as described for the 
WB antigen. Wells were coated with Con A, washed, 
incubated with a 1:100 dilution of the cell lysate and 
blocked, as described for the inhibition ELISA. After 
incubation with serial dilutions of monkey plasma for 
1.5h at 37°C, wells were incubated with biotin- 
conjugated goat-anti-human IgG and H R PO-conj ugated 
streptavidin. Substrate reaction was carried out as 
described for the inhibition ELISA. 
Detection of SIV and SIV nucleic acid in monkeys 
Virus isolation. Virus isolation was carried out by 
co-cultivation of 10 6 PBMC with 2.5 x 105 C8166 cells 
in 1 ml 10% FCS RPMI-GPSM in the presence of 50/tg 
phytohaemagglutinin ml 1 Cells were incubated at 37°C 
for 3 4 weeks. Culture supernatants were refreshed twice 
a week and at regular time intervals tested for the 
presence of p27 protein by either Organon or Coulter p27 
antigen detection kits. All positive results were confirmed 
by running the samples again in the same assay. 
Polymerase chain reaction (PCR).  PCR reaction was 
carried out essentially according to the method described 
by Kitchin et al. 34 with minor modifications, as described 
by Niphuis et al. (personal communication). 
RESULTS 
SIV-specific serum antibody responses after immunization 
SIV-MDP-immunized monkeys. The monkeys of 
groups A and B immunized with SIV-MDP all developed 
serum antibodies which after the second immunization 
reacted predominantly top27 in WB analysis, as is shown 
for two of these animals in Figure2. With the 
gpl20-inhibition ELISA, serum antibodies to gpl20 
could also be demonstrated after the second immuniz- 
ation, with titres ranging from 100 to 1600. These titres 
rapidly declined, but returned to approximately the same 
levels after the following two immunizations (Fiqure 3a 
Figure 2 SIV WB analysis of the antibody development in SIV-MDP- and 
SIV-ISCOM-immunized monkeys at 0, 6, 12 and 18 weeks after the first 
immunization. Monoclonal antibodies directed against gp160/120 (bands 
indicated by O), p55/p27 (bands indicated by *) (pooled in lane a) and 
gp160/32 (lane b) were used as controls 
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Figure 3 Antibody development in monkeys immunized with MV-MDP and MV-ISCOM (x) ,  SIV-MDP (m) and SIV-ISCOM (O) after immunization 
and after challenge with cell-free virus (group A; (a) and (c)) or cell-associated virus (group B; (b) and (d)) as measured in gp120-inhibition ((a) and 
(b)) and gp32-inhibition ((c) and (d)) ELISA. Day of immunization and day of challenge are indicated by arrows 
and b). Antibodies to gp32 as measured in the 
gp32-inhibition ELISA, could only be demonstrated in 
four of the eight immunized animals and the titres 
remained consistently ower than 100 (Figure 3c and d). 
SIV neutralizing serum antibodies were detectable in all 
the SIV-MDP-immunized monkeys at the day of 
challenge with titres ranging from 24 to 538 (Table 1). 
SIV-ISCOM-immunized monkeys. The monkeys of 
groups A I and B immunized with SIV-ISCOM all 
developed serum antibodies to p27 and gpl20 detectable 
in WB analysis after the second immunization, as is 
shown for two of these animals in Figure2. Serum 
antibodies to gpl20 and gp32 were demonstrated in all 
these monkeys after the second immunization (Figure 3a, 
b, c and d). At week 6 gpl20 antibody titres were 
significantly higher (mean of log titres +s.d., 3.37_+0.25 
in group A! and 3.50_+0.28 ingroup B) than those found 
in the SIV-MDP-immunized animals (2.53_+0.48 in 
group A1 and 2.75_+0.35 in group B). At the day of 
challenge gpl20 antibody titres were higher in group A1 
in SIV-ISCOM-immunized monkeys (3.40_+ 0.15) than in 
SIV-MDP-immunized animals (2.55_+0.37). However, 
in group B only a minor difference between gpl20 
antibody titres in SIV-ISCOM- and SIV-MDP- 
immunized monkeys was seen (3.55 _+ 0.30 and 3.25 _+ 0.37, 
Table 1 SIV-VN antibody titres in group A1 and B monkeys at the day 
of the first challenge and 6 weeks after challenge 
Group A1 Group B 
Weeks Weeks 
postchallenge postchallenge 
Immunized 
with Monkey 0 6 Monkey 0 6 
SIV-MDP 4083 80 < 14 8645 538 48 
4094 20 < 14 8649 190 20 
lXD 95 24 I lM 190 320 
3B 24 < 14 KP 80 227 
SIV-ISCOM 4053 453 80 4097 34 227 
8656 a NT NT 8653 905 538 
1XV 95 < 14 8668 269 57 
1YB 160 17 8730 453 40 
MV-MDP 4060 < 14 2560 1YH < 14 80 
IIH <14 113 2CA <14 <14 
MV-ISCOM 8789 < 14 < 14 8672 < 14 < 14 
8791 < 14 2153 8679 < 14 33 
SIV-infected (1XC) 2153 
NT, not tested 
~Monkey died during recovery from anaesthesia on the day of 
challenge 
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respectively), which most probably can be explained by 
the different immunization schedules for groups AI and 
B. SIV neutralizing serum antibodies were detectable in
all the SIV-ISCOM-immunized animals at the day of 
challenge and the titres in group A1 monkeys, but not 
in group B monkeys, were generally higher than those 
found in the SIV-MDP-immunized monkeys (Table 1). 
Upon immunization one of the MV-immunized 
monkeys developed SIV-specific serum antibodies 
detectable in any of the assays used. 
sir-specific serum antibody response after SIV challenge 
SIV-MDP-immunized monkeys, challenged with cell- 
fi'ee SIV (group A I). WB analysis of the sera from the 
SIV-MDP-immunized monkeys challenged with cell-free 
SIV, did not show changes in the patterns observed after 
immunization (not shown). Serum antibody titres 
measured in the gpl20- and gp32-inhibition ELISAs 
gradually declined after challenge (Figure 3a and c). Also 
the VN serum antibody titres to SIV had largely 
disappeared within 6 weeks after challenge (Table 1). 
SIV-ISCOM-immunized monkeys challenged with 
cell-ji'ee SIV (group A1). As with the SIV-MDP- 
immunized monkeys, WB analysis of the sera from three 
SIV-ISCOM-immunized monkeys, challenged with cell- 
free S1V, did not show changes in the patterns observed 
after immunization ( ot shown). Serum antibody titres 
measured in the gpl20 and gp32 ELISAs also declined 
gradually after challenge (Figure 3a and c) and the VN 
serum antibody titres of these monkeys to SIV also 
declined uring 6 weeks after challenge (Table 1). 
MV-MDP- and MV-ISCOM-immunized monkeys 
challenged with cell-free SIV (group A1). Three out of 
four of the MV-immunized monkeys (4060, 8791, IIH) 
challenged with cell-free SIV developed p27-specific 
serum antibodies detectable in WB analysis within 4 
weeks after challenge (data not shown). These three 
monkeys also developed gpl20- and gp32-specific serum 
antibodies detectable in the inhibition ELISAs, within 4 
weeks after challenge. The titres in the gpl20-inhibition 
ELISA reached levels similar to those found in the 
SIV-ISCOM-immunized animals, whereas those found 
in the gp32-inhibition ELISA largely exceeded those of 
the SIV-MDP- and SIV-ISCOM-immunized monkeys 
(Figure 3a and c). In these three monkeys SIV neutralizing 
serum antibodies were also detected within 6 weeks after 
challenge, with titres ranging from 113 to 2560 (Table 1). 
The fourth monkey (8789), which had remained 
seronegative in all these assays, became viraemic and died 
soon after challenge (see below). 
SIV-MDP-immunized monkeys challenged with cell- 
associated SIV (group B). WB analysis of the sera from 
two out of four (8645 and 8649) SIV-MDP-immunized 
monkeys challenged with cell-associated SIV, did not 
show changes in the patterns observed after immunization, 
whereas the serum samples of the two ther monkeys in 
this group (IIM and KP) showed an increased staining 
of the gpl20 protein after challenge (Figure4). Serum 
antibody titres measured in the gpl20- and gp32- 
inhibition ELISAs gradually declined after challenge in 
two monkeys (8645 and 8649) and strongly increased in 
the two other monkeys (IIM and KP) within 4 weeks 
Figure 4 SIV WB analysis of the antibody development in SIV-MDP- and 
SlV-lSCOM-immunized monkeys at 0, 6 and 12 weeks after challenge 
with cell-associated virus (group B). Monoclonal antibodies directed 
against gp160/120 (lane a), gp 160/32 (lane b) and p55/27 (lane c) were 
used as controls 
after challenge, with titres ranging from 25 600 to 409 600 
(Figure3b and d). In contrast o this 256- to 512-fold 
increase in titre, VN serum antibody titres in these two 
monkeys showed a less than threefold increase (Table 1). 
SIV-ISCOM-immunized monkeys challenged with 
cell-associated SIV (group B). Although in WB 
analysis of the sera from SIV-ISCOM-immunized 
monkeys, challenged with cell-associated SIV, no clear 
changes in the patterns observed after immunization 
could be demonstrated (Figure 4), serum antibody titres 
measured in the gpl20- and gp32-inhibition ELISAs 
proved to decline gradually after challenge in two out of 
four monkeys (8668 and 8730) and strongly increased in 
the two other monkeys (4097 and 8653) within 4 weeks 
after challenge, with titres ranging from 25 600 to 409 600 
(Figure3b and d). In contrast o this 16- to 256-fold 
increase, VN serum antibody titres in one monkey (4097) 
showed a sevenfold increase and in another monkey 
(8653) a decrease during 6 weeks after challenge (Table 1). 
MV-MDP- and MV-ISCOM-immunized monkeys 
challenged with cell-associated SIV (group B). All four 
of the MV-immunized monkeys challenged with cell- 
associated SIV developed p27-specific serum antibodies 
detectable in WB-analysis, within 4 weeks after challenge 
(data not shown). These monkeys also developed 
gpl20- and gp32-specific serum antibodies detectable 
within 9 or 6 weeks in the respective inhibition ELISAs 
(Figure 3). Twelve weeks after challenge antibody titres 
measured in the gpl20-inhibition ELISA were tenfold 
lower than antibody titres induced by SIV-ISCOM 
immunization. Six weeks after challenge low VN 
antibody titres were detected in two of the four monkeys 
(8679 and 1YH). 
SIV isolation and PCR analysis after challenge 
After intravenous challenge with cell-free SIV (group 
A1), viraemia was not demonstrated in any of the 
monkeys immunized with SIV-MDP or SIV-ISCOM as 
measured in SIV isolation and SIV-specific PCR (Table 
2). In contrast, all four MV-immunized monkeys howed 
viraemia, since SIV was isolated from PBMC of all these 
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monkeys at 4, 9 and 12 weeks after challenge and all 
monkeys were positive in the SIV-specific PCR at 10, 12 
and 41 weeks. One monkey (8656) died during recovery 
from anaesthesia on the day of challenge. 
After intravenous challenge with cell-associated SIV 
(group B), no viraemia was demonstrated in two out of 
four SIV-MDP (8645 and 8649) and two out of four 
SIV-ISCOM (8668 and 8730) immunized monkeys, ince 
SIV was not isolated from these monkeys and monkeys 
were negative in the PCR. After transfer of PBMC of 
these monkeys to naive monkeys no SIV infection could 
be detected in the recipients (Table 2). In contrast, the 
other SIV-immunized monkeys and all four MV- 
immunized monkeys howed viraemia: SIV was isolated 
from PBMC at 2, 4, 6, 9 and 12 weeks after challenge 
and all monkeys were positive in SIV-specific PCR at 8, 
12 and 52 weeks. 
Cell-specific antibody responses at day of first SIV 
challenge 
Since it has been shown that non-virus-specific cellular 
antigens present in the SIV vaccine preparations may 
play a role in protection, antibodies directed to C8166 
cell antigen or rhesus PBMC were measured in cell 
protein ELISA at the day of irst challenge of monkeys 
in groups A1 and B. It was shown that all immunized 
monkeys developed cell-specific antibodies and that the 
protection found in group B did not correlate with the 
levels of plasma antibody titres to C8166 cells or rhesus 
PBMC in the SIV-immunized monkeys (Figure 5). 
Outcome of rechailenge of protected monkeys of group 
A with cell-free SIV propagated in rhesus PBMC 
To study whether the protection observed in the 
SIV-immunized monkeys of group A was conferred by 
SIV-specific immunity, all protected monkeys and two 
control animals were reimmunized with the respective 
SIV antigens and subsequently rechallenged with cell-free 
SIVmac (32H) propagated in rhesus PBMC (group A2). 
All animals developed SIV-specific antibody titres, as 
measured in inhibition ELISAs, approximately similar 
to those measured at the day of the first SIV challenge 
(Figures 3 and 6). Low SIV-VN antibody titres ranging 
from 17 to 227 were observed at the day of rechallenge. 
Two weeks after rechallenge all seven SIV-immunized 
monkeys howed a strong increase of antibody titres 
Table 2 SIV detection by virus isolation (VI) from monkeys PBMC and PCR of PBMC and development of clinical disease in group A1 and B monkeys after challenge 
Vi a at weeks  PCR a at weeks  
postcha l lenge postcha l lenge 
Monkey:  Immunized  Transfer  Cl in ical  
Group A1 with 2 4 6 9 12 of PBMC ~ 6 12 41 d isease  c 
4083 S IV-MDP ND - ND - - ND -- -- - 
4094 ND - ND - ND 
1XD ND -- ND - -- ND - - - 
3B ND - -  ND - ND - 
4053 SIV- ISCOM ND - ND - - ND - -- - 
8656 ~ 
1XV ND - ND - - ND -- -- - 
1YB ND - ND - - ND -- -- - 
4060 MV-MDP ND + ND + + ND + + + 
I lH  ND + ND + + ND + + + 
8789 MV- ISCOM ND + ND + + ND + + + 
8791 ND + ND + + ND + + + 
m 
m 
AIDS (w79) 
AIDS (w26) 
weeks  
postcha l lenge 
Group  B 8 12 52 at w85 
8645 
8649 
I lM  
KP 
4097 
8653 
8668 
8730 
SIV-MDP 
SIV- ISCOM 
_ L 
+ + + 
+ + + 
+ + + 
+ + + 
1YH MV-MDP + + + 
2CA + + + 
8672 MV- ISCOM + + + 
8679 + + + 
- -  I 
+ + + + + + AIDS (w35) 
+ + ND + + + AIDS (w54) 
+ + ND + + + -- 
+ + ND + + + -- 
+ + ND + + + AIDS (w85) 
+ + ND + + + -- 
+ + ND + + + AIDS (w39) 
+ + ND + + + CD4~ 
ND, not done 
aPresence  or absence  of SIV is indicated by + or - respectively 
bPBMC transfer (taken from Ref. 35) 
CDevelopment of clinical symptoms during 91 (w91) and 85 weeks (w85) postchallenge infection in monkeys of group A1 and B, respectively, is indicated 
by: - ,  no clinical symptoms observed; AIDS: monkey died from AIDS at indicated week postchallenge; CD4J.: reduced number of circulating CD4+ 
T cells observed (taken from Ref. 35) 
dMonkey d ied dur ing  recovery  f rom anaesthes ia  at day of cha l lenge  
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measured in gp32-inhibition ELISA and within 4 weeks 
in gpl20-inhibition ELISA (Figure6). SIV was isolated 
from all seven S1V-immunized and from the two 
MV-ISCOM-immunized control monkeys (3268 and 
3980) (Table 3). 
2,500 
O .o 
< 
03 
m 
d 
LU 
_ - -  + + + + 
250 - 
coco>ha 
Group A Monkey Group B 
Figure 5 C8166 cell-specific (m) and rhesus PBMC-specific (1~) 
antibody titre of SlV-MDP- and SlV-lSCOM-immunized monkeys at the 
day of the first challenge. Protected ( ) and unprotected (+)  monkeys 
are indicated 
gp120-inhibition ELISA titer A 
<6, ~- - - - -N  _~__~2_-  ~-~ , ___l 
-2 0 2 4 6 8 10 12 
Weeks after challenge 
Development of clinical disease in viraemic animals of 
group B 
The two SIV-MDP-immunized monkeys (I1M and 
KP) that became viraemic after challenge with 
cell-associated SIV, developed AIDS and died at 35 and 
54 weeks after infection respectively, whereas the two 
viraemic SIV-ISCOM-immunized monkeys (4097 and 
6853) of this group did not develop clinical signs of AIDS 
up to 85 weeks after infection (Table2), Two of the 
MV-immunized monkeys (8672 and IYH) died at 39 and 
85 weeks after challenge, respectively, and one monkey 
(8679) showed reduced numbers of circulating CD4 + T 
cells. Monkey 2CA of this group did not show any clinical 
signs up to 85 weeks after challenge. 
D ISCUSSION 
In the present paper we have shown that immunization 
with different SIV vaccine preparations may induce 
protection against either cell-free or cell-associated SIV 
challenge. It could not be demonstrated that the 
protection observed in the monkeys of group A l, 
immunized with SIV-ISCOM or SIV-MDP and 
challenged with cell-free SIV, was indeed mediated by 
SIV-specific immunity. None of these monkeys proved 
to be protected from a rechallenge with SIV propagated 
in rhesus PBMC (Figure6). This is in line with 
observations by several other groups, who have shown 
that protection against human-cell propagated SIV was, 
at least in part, due to immunity to cellular 
components 1619. From the data presented on the 
monkeys of group B, we conclude that the protection 
observed in four out of these eight monkeys, immunized 
with either SIV-ISCOM or SIV-MDP and challenged 
with cell-associated SIV, must have been elicited by 
SIV-specific immunity, since the challenge virus and the 
vaccine preparation had not been propagated in cells 
from the same species. Interestingly, our observations in
group B also suggested that in contrast o SIV-MDP, 
SIV-ISCOM protected from disease development after 
challenge with cell-associated SIV. 
To our knowledge this is the first demonstration of
vaccine-induced protection against challenge with 
SIV-infected cells of the same host species. Similar 
gp32-inhibition ELISA titer B 
25 ,000~ 
-2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 
Weeks after challenge 
Fiflure 6 Antibody development in monkeys immunized with 
MV-ISCOM (x ) ,  SlV-MDP ( I )  and SlV-lSCOM (O) after boosting and 
after rechallenge with cell-free virus propagated in rhesus PBMC (group 
A2) as measured in (a) gp120-inhibition and (b) gp32-inhibition ELISAs. 
Day of immunization and day of challenge are indicated by arrows 
Table 3 SIV detection in rhesus monkeys after rechallenge with SIV- 
mac (32H) grown in rhesus PBMC (group A2) by virus isolation (Vl) and 
PCR from monkey PBMC and development of clinical disease a 
Vl at weeks PCR at weeks 
postchallenge postchallenge 
Immunized 
Monkey with 2 4 4 8 
4083 SIV-MDP + + - 
4094 + ND ~ + 
1XD + + + + 
3B + ÷ + 
4053 SIV-ISCQM + + + ~- 
1XV + + 4_ + 
1YB + ± + + 
3268 MV-ISCOM + + + + 
3980 + + ÷ + 
aSee legend to Table 2 
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observations have been made in chimpanzees immunized 
with HIV-1 vaccine preparations and challenged with 
HIV-l-infected PBMC 36. 
The mechanism of protection observed in group A1 
monkeys can at least in part be explained by the presence 
of anti-C8166 immunity. This was indicated by 
demonstrating the presence of ceil-specific antibodies in 
monkeys of group A. The lack of protection against 
cell-free SIV challenge propagated in rhesus PBMC, 
suggested that the levels of SIV-specific protective 
immunity induced by both vaccines were not sufficient 
to impart protection against his challenge. We cannot 
exclude that during the in vitro propagation of this 
challenge virus in rhesus PBMC, changes in virulence or 
sequence as compared with the original SIVmac- 
sequenced 32H pool 11/88 challenge stock may have 
occurred 24. Both SIV vaccine preparations must have 
induced SIV-specific immunity, although not sufficient 
to protect against his cell-free challenge, since four out 
of the eight SIV-immunized monkeys proved to be 
protected against challenge with SIV-infected PBMC 
(group B). Neither cell-specific nor SIV-specific antibody 
titres, as measured by ELISA and SIV-VN assay, 
correlated with the protection found in these four 
monkeys (Fi#ures 5 and 6; Table I). Recently, we found 
that the protected monkeys hare the MHC class I A26 
allele with the PBMC donor monkey 1XC. We concluded 
that the mechanism ofprotection ismost probably based 
on SIV-specific immunity, since sharing of the MHC class 
I A26 allele with the donor monkey alone, as is the case 
for two MV-immunized monkeys (8679 and 2CA), proved 
not to be sufficient for the induction of protection. Our 
present studies address the possible mechanisms bywhich 
this protection was induced. An attractive speculation 
would be the induction of SIV-specific MHC class 
I-restricted cytotoxic T cells, as we have recently 
suggested 35. 
Although comparison of the results obtained with the 
SIV-MDP and the SIV-ISCOM preparations showed 
that the ISCOM preparation i duced higher antibody 
titres, no difference between the SIV-MDP and the 
SIV-ISCOM preparation was observed with respect o 
the induction of protection to infection. However, the 
development of disease symptoms after infection seemed 
to be different in the two groups. The SIV-ISCOM- 
immunized animals of group B have not yet developed 
any clinical symptoms during the observation period, 
whereas most of the other animals of this group did 
develop evidence of disease progression. 
It is known from several studies that the ISCOM, in 
contrast to other non-replicating antigen-presenting 
forms, is effective in inducing virus-specific CD8+ T 
cells, as has been described for HIV-1, measles virus 
and influenza virus 22"37. We are currently investi- 
gating whether indeed CD8+ T-cell responses were 
induced upon immunization with the respective vaccine 
preparations. 
The role of SIV-specific antibodies in protection 
remains unclear. Both SIV preparations induced low VN 
antibody titres compared with titres that could be 
measured in some of the SIV-infected monkeys (Table 1). 
This may have been caused by the presence of a denatured 
form of gpl20 after formaldehyde or acid treatment in
both vaccine preparations. Therefore, in future experi- 
ments recombinant SIV gp160 proteins incorporated into 
the ISCOM matrix under mild denaturing conditions, as 
Vaccination against  SIV: P. de Vries et al. 
described for HIV-1 gpl60 proteins 2~, will be tested 
for their capacity to induce SIV-VN antibodies and 
protection against challenge virus grown on rhesus 
PBMC. Further study of the mechanisms leading to the 
protection from infection and disease development 
observed in this animal model, may provide clues for the 
development ofa vaccine against HIV. 
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